




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

# Immunity

## The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells

### Graphical abstract



### Authors

Ashraf S. Yousif, Larance Ronsard, Pankaj Shah, ..., Alejandro B. Balazs, Hans-Christian Reinecker, Daniel Lingwood

### Correspondence

dlingwood@mgh.harvard.edu

### In Brief

Hyper-elevated IL-6 underscores cytokine storming and chronic inflammatory disorders. Yousif et al. demonstrate that conventional dendritic cells are a major source of sIL-6R, which forms a buffer system that sets the in-solution persistence of IL-6, regulating inflammatory immune reactions.

### Highlights

- DC-derived sIL-6R gates plasma cell differentiation to adjuvant antibody responses
- DC-derived sIL-6R captures IL-6 released after bacterial or viral challenge
- TLR ligation, then cell surface sheddase activity, mediates sIL-6R release from DCs



## Report

# The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells

Ashraf S. Yousif,<sup>1</sup> Larance Ronsard,<sup>1</sup> Pankaj Shah,<sup>2</sup> Tatsushi Omatsu,<sup>2</sup> Maya Sangesland,<sup>1</sup> Thalia Bracamonte Moreno,<sup>1</sup> Evan C. Lam,<sup>1</sup> Vladimir D. Vrbancac,<sup>1</sup> Alejandro B. Balazs,<sup>1</sup> Hans-Christian Reinecker,<sup>2,3</sup> and Daniel Lingwood<sup>1,4,\*</sup>

<sup>1</sup>The Ragon Institute of Massachusetts General Hospital, The Massachusetts Institute of Technology and Harvard University, 400 Technology Square, Cambridge, MA 02139, USA

<sup>2</sup>The Center for the Study of Inflammatory Bowel Disease, Center for Computational and Integrative Biology, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA

<sup>3</sup>The Center for the Genetics of Host Defense, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA

<sup>4</sup>Lead contact

\*Correspondence: [dlingwood@mgh.harvard.edu](mailto:dlingwood@mgh.harvard.edu)

<https://doi.org/10.1016/j.immuni.2020.12.001>

## SUMMARY

The interleukin-6 (IL-6) membrane receptor and its circulating soluble form, sIL-6R, can be targeted by antibody therapy to reduce deleterious immune signaling caused by chronic overexpression of the pro-inflammatory cytokine IL-6. This strategy may also hold promise for treating acute hyperinflammation, such as observed in coronavirus disease 2019 (COVID-19), highlighting a need to define regulators of IL-6 homeostasis. We found that conventional dendritic cells (cDCs), defined in mice via expression of the transcription factor *Zbtb46*, were a major source of circulating sIL-6R and, thus, systemically regulated IL-6 signaling. This was uncovered through identification of a cDC-dependent but T cell-independent modality that naturally adjuvants plasma cell differentiation and antibody responses to protein antigens. This pathway was then revealed as part of a broader biological buffer system in which cDC-derived sIL-6R set the in-solution persistence of IL-6. This control axis may further inform the development of therapeutic agents to modulate pro-inflammatory immune reactions.

## INTRODUCTION

Interleukin-6 (IL-6) is a potent pro-inflammatory cytokine released following immune challenge or tissue injury, where it broadly stimulates innate and adaptive immune reactions (Kishimoto, 2010; Tanaka et al., 2014). Overexpression of IL-6 can lead to chronic inflammatory disorders (Spencer et al., 2019; Tanaka et al., 2016) and potentially fatal hyperinflammation, such as seen during advanced coronavirus disease 2019 (COVID-19) (McElvaney et al., 2020; Mehta et al., 2020). Hyperinflammatory states can be treated by antibody blockade therapies targeting the IL-6 receptor (IL-6R) and its soluble circulating form (sIL-6R) (Tanaka et al., 2016, 2018), and some early clinical studies have reported successful application to treat COVID-19 (Biran et al., 2020; Somers et al., 2020; Xu et al., 2020), underscoring the importance of defining the homeostatic factors that regulate immune signaling through IL-6.

IL-6 classic signaling occurs when this cytokine engages IL-6R on a target cell co-displaying gp130, the receptor's signaling subunit (Rose-John, 2012; Wolf et al., 2014). IL-6R expression, and thus IL-6 classic signaling, is largely restricted to immune cells and hepatocytes (Rose-John, 2012; Tanaka et al., 2014).

In contrast, surface gp130 is more widely expressed, enabling IL-6 *trans* signaling via the complex formed between IL-6 and circulating sIL-6R (Rose-John, 2012; Wolf et al., 2014). Operationally, these IL-6 signaling modes can be distinguished by the circulating form of gp130 (sgp130), which inhibits the latter but not former (Jostock et al., 2001; Tenhumberg et al., 2008). IL-6 classic signaling is implicated in acute-phase responses, whereas IL-6 *trans* signaling typically initiates pro-inflammatory pathways (Rose-John, 2012; Scheller et al., 2006). IL-6 classic signaling is also important for production of hepatocyte growth factor during liver regeneration but can be substituted by the *trans* signaling mode (Fazel Modares et al., 2019).

sIL-6R and sgp130 are also thought to comprise a biological buffer system that is predicted to regulate IL-6 half-life in blood (Rose-John, 2012, 2017; Scheller and Rose-John, 2012). In healthy humans, serum IL-6 is nearly undetectable (2–6 pg/mL), whereas the concentrations of sIL-6R and sgp130 are in molar excess (Rose-John, 2012, 2017; Scheller and Rose-John, 2012), stoichiometries that are also conserved in mice (Doganci et al., 2005; Schuett et al., 2012). IL-6 binds sIL-6R with nanomolar affinity, and the IL-6:sIL-6R complex engages inhibitory sgp130 with picomolar affinity, suggesting that free



IL-6 is captured and neutralized rapidly at steady state (Rose-John, 2012, 2017; Scheller and Rose-John, 2012). In pro-inflammatory states, sIL-6R is elevated, whereas sgp130 stays relatively constant, enabling IL-6 *trans* signaling through molar excess of sIL-6R (Rose-John, 2012, 2017; Scheller and Rose-John, 2012; Tanaka et al., 2014).

The capacity of sIL-6R to set the half-life of free IL-6 and restrict its systemic signaling has not been validated experimentally *in vivo* (Baran et al., 2018). One issue is that sIL-6R is generated post-translationally and is difficult to manipulate. Cell culture systems have implicated A disintegrin and metalloenzymes (ADAMs) as sheddases that catalyze sIL-6R release from surface IL-6R (Chalaris et al., 2007; Garbers et al., 2014; Matthews et al., 2003; Müllberg et al., 1994, 1995; Riethmueller et al., 2016; Vollmer et al., 1996), but their genetic depletion is lethal in mice, and cell-specific depletion of ADAM sheddases has failed to alter sIL-6R set point *in vivo* (Garbers et al., 2011; Schumacher et al., 2015, 2016). The cellular sources of sIL-6R are also only broadly defined; cell-specific depletion of IL-6R using *Alb cre* and *Lyz2 cre* shows 40% and 60% reduction in circulating sIL-6R (McFarland-Mancini et al., 2010). *Alb* is selective for murine hepatocytes (Weisend et al., 2009), but *Lyz2* is expressed in numerous cell lineages, including monocytes and macrophages, CD11c<sup>+</sup> dendritic cells, granulocytes, and type II lung alveolar cells (Shi et al., 2018).

Using a combination of bone marrow chimeras and validated cell-specific approaches to deplete IL-6R, we show that conventional dendritic cells (cDCs), defined in mice by expression of the transcription factor *Zbtb46* (Meredith et al., 2012; Satpathy et al., 2012a), play a central role in maintaining systemic sIL-6R. DCs connect the innate and adaptive immune systems by priming T cells (Alvarez et al., 2008; Henrickson et al., 2013), which is necessary for thymus-dependent (TD) B cell responses, underscoring humoral immunity (Stebegg et al., 2020; Tesfaye et al., 2019). We identified cDC control over systemic sIL-6R by uncovering a modality that modulates TD antibody output independent from T cell priming. In this pathway, cDC-derived sIL-6R enabled IL-6 *trans* signaling at the B cell surface, promoting differentiation to antibody-secreting plasma cells. We further demonstrate that cDC-derived sIL-6R captures the free IL-6 released following bacterial and viral challenges. Here induction of sIL-6R release required Toll-like receptor (TLR) ligation followed by ADAM sheddase activity. Our study establishes cDC-derived sIL-6R as a core component of a biological buffer system regulating in-solution persistence of IL-6 and, consequently, immune signaling through this cytokine.

## RESULTS

### A cDC-dependent but T cell-independent axis that regulates antibody output

We first evaluated splenic antibody responses following intravenous challenge with influenza viral glycoprotein hemagglutinin (HA), an extensively described protein antigen (Altman et al., 2018; Angeletti et al., 2017). Immunoglobulin G (IgG) and IgM responses were lost following splenectomy, whereas only IgG output was reduced in *Tcra*<sup>-/-</sup> mice (Figure 1A). When cDCs were depleted in *Zbtb46*-diphtheria toxin receptor (DTR) bone marrow chimeras (Meredith et al., 2012; Satpathy et al., 2012a),

IgG and IgM output was reduced significantly (Figure 1A). The chimeras did not show a defect in antigen uptake within the spleen (Figure S1B). Reduction in IgG was expected in the absence of DC-primed T cell help (O et al., 2014), but co-reduction in the T cell receptor (TCR)-independent IgM response suggested that cDCs may also regulate humoral immunity independent of T cell priming. We confirmed this for other non-HA antigens, including HIV gp120 and ovalbumin (Figures S1C and S1D). The IgM response could be rescued in mixed chimeras containing 50% *Zbtb46* DTR:50% major histocompatibility complex (MHC) class II-deficient (homozygous *H2<sup>dIAb1-Ea</sup>*); diphtheria toxin (DT)-treated animals raised no IgG (indicating successful depletion of cDC-bearing MHC class II) but retained the native IgM response in the MHC class II-deficient background (Figure 1A). Accordingly, we proceeded to use IgM elicitation as a readout to identify factors responsible for T cell-independent but cDC-dependent control over humoral immunity (Figure 1B).




### Genetic ablation of IRF5 and IL-6 (but not IL-12 or IFNAR) functionally recapitulates the IgM response defect

We hypothesized that cDCs may exert effects through secreted molecules and that interferon regulatory factor 5 (IRF5) could be important because it is needed for generating IL-12 and IL-6 (Takaoka et al., 2005), cytokines that support humoral immune reactions (Dubois et al., 1998; Karnowski et al., 2012; Kim et al., 2008; Tanaka et al., 2014). Indeed, we recapitulated the IgM response deficit in the *Irf5*<sup>-/-</sup> and *Il6*<sup>-/-</sup> genotypes but not in *Il12p40*<sup>-/-</sup> or *Ifnar1*<sup>-/-</sup> mice (Figures 1C and S1E). Injection of *Irf5*<sup>-/-</sup> mice with recombinant IL-6 partially rescued IgM and IgG titers (Figure 1C), consistent with IL-6 dependence and an independence from interferon- $\alpha/\beta$  receptor (IFNAR) signaling. All immunizations were performed using Sigma adjuvant, which deploys bacterial lipid A, a well-described stimulator of IL-6 release (Matsuura et al., 1999; Wang et al., 1991).

### cDCs set the circulating concentration of sIL-6R, which is needed for efficient antibody responses

If the IgM response deficits represented the same IL-6-dependent but IFNAR-independent pathway, we hypothesized that IRF5 signaling was needed to produce IL-6 by cDCs and/or that IL-6R derived from cDCs was needed to support IL-6 signaling. Accordingly, we generated mice in which IL-6R or IRF5 was depleted under *Zbtb46*. B cell, T cell, macrophage, and DC subsets were phenotypically similar in these genotypes (Figure S2), and cDCs showed selective depletion of IL-6R in cDC-*IL6ra*<sup>-/-</sup> (Figure 2A) and reduction in total IRF5 in cDC-*Irf5*<sup>-/-</sup> (Figure 2B). Antibody responses were unaffected in cDC-*Irf5*<sup>-/-</sup>, but IgM (and IgG) response deficits occurred in cDC-*IL6ra*<sup>-/-</sup> (Figure 2C). Serum sIL-6R was also strongly reduced in this genotype (Figure 2D), and injection of recombinant sIL-6R rescued IgM and IgG output (Figure 2E). Thus, cDCs are a major source of sIL-6R, and sIL-6R is one factor in T cell-independent control over B cell priming.

The majority of the serum sIL-6R was also lost in *Zbtb46*-DTR chimeras and restored in mixed chimeras (50% *Zbtb46* DTR:50% MHC class II deficient) (Figure S3A). We also examined *Batf3*<sup>-/-</sup> mice, which are depleted for cDC1 (Hildner et al., 2008; Figure S3B). *Zbtb46* does not discriminate between cDC1 or cDC2 (Figure SB). We found that cDC1 (a minor cDC




**Figure 1. cDC-dependent but TCR-independent control over IgM responses to influenza hemagglutinin (HA), a model TD antigen**

(A) Serum IgM versus IgG responses against HA that was injected intravenously along with lipid A adjuvant ( $n = 5$  animals per group). The responses were elicited in the following groups: splenectomized versus sham control,  $Tcra^{-/-}$  versus WT,  $Zbtb46$ -DTR chimeras receiving versus not receiving DT, and chimeras containing 50%  $Zbtb46$ -DTR:50% MHC class II-deficient (homozygous  $H2^{dIAb1-Ea}$ ) receiving versus not receiving DT. The dilution curves (mean  $\pm$  SD) were quantified by endpoint dilution; \*\* $p < 0.02$ , \*\*\* $p < 0.001$ , Student's  $t$  test.

(B) These data provide functional evidence of a cDC-dependent but T cell-independent mechanism modulating humoral output (red arrow).

(C) Recapitulation of the IgM (and IgG) response deficits to HA via genetic ablation of IL-6 and IRF5 but not IL-12 ( $n = 5$  animals per group). Antibody response deficits could be rescued by addition of recombinant murine IL-6. The dilution curves were quantified by endpoint dilution; \*\* $p < 0.005$ , \* $p < 0.05$ , ANOVA with Tukey's test. See [Figure S1](#) for chimera methodology, orthogonal demonstration using non-HA antigens, and antibody responses in  $Irfar1^{-/-}$  mice.



**Figure 2. cDCs set the circulating concentration of sIL-6R, and this regulates antibody responses**

(A) Histograms reporting surface IL-6R in immune cells from WT, cDC-*Irf5*<sup>-/-</sup>, and cDC-*Il6ra*<sup>-/-</sup> mice (B cells = B220<sup>+</sup>/CD3<sup>-</sup>, T cells = CD3<sup>+</sup>/B220<sup>-</sup>, cDCs = CD3<sup>-</sup>/B220<sup>-</sup>/MHCII<sup>+</sup>/CD11c<sup>hi</sup>, tissue resident macrophages = CD3<sup>-</sup>/B220<sup>-</sup>/CD11b<sup>+</sup>/F4-80<sup>+</sup>). Quantification of these data is presented as the proportion of cells expressing surface IL-6R (mean ± SD, n = 3 per group, \*\*\*p < 0.001, ANOVA with Tukey's test).

(B) Total IRF5 was measured in cDCs (B220<sup>-</sup>/CD3<sup>-</sup>/CD11c<sup>hi</sup>/MHCII<sup>+</sup>) isolated by fluorescence-activated cell sorting (FACS) on splenocytes of WT and cDC-*Irf5*<sup>-/-</sup> animals. The sorted cDCs (200,000 cells) were lysed, separated by SDS-PAGE, and immunoblotted for either IRF5 or β-actin.


(C) Serum IgM versus IgG responses against HA (with lipid A adjuvant) in transgenic mice (mean ± SD, n = 4 animals per group). The dilution curves were quantified by endpoint dilution; \*\*p < 0.01, ANOVA with Tukey's test.

(D) Serum sIL-6R as measured in WT, cDC-*Irf5*<sup>-/-</sup>, and cDC-*Il6ra*<sup>-/-</sup> (mean ± SD, n = 4 animals per group); \*\*\*\*p < 0.0001, ANOVA with Tukey's test.

(E) Co-injection of recombinant murine sIL-6R rescued the IgM and IgG responses to HA (with lipid A adjuvant) in cDC-*Il6ra*<sup>-/-</sup> animals (mean ± SD, n = 4 animals per group). The dilution curves were quantified by endpoint dilution; \*\*p < 0.01, ANOVA with Tukey's test.

See also [Figures S2](#) and [S3](#) for immune cell subsets in cDC-*Il6ra*<sup>-/-</sup> and cDC-*Il6ra*<sup>-/-</sup>, sIL6R concentration in cDC-DTR, and IL6R expression by cDC1 and cDC2 in cDC-*Il6ra*<sup>-/-</sup> and *Batf3*<sup>-/-</sup>.





**Figure 3. cDC-derived sIL-6R gates antibody responses by controlling plasma cell differentiation**

(A) Surface expression of gp130 on B cells (B220<sup>+</sup>/CD3<sup>-</sup>, gate I) versus plasmablasts (CD3<sup>-</sup>/B220<sup>lo</sup>/CD138<sup>+</sup>, gate II) isolated from spleen of WT mice. The splenocytes were either left unstimulated or exposed to sIL-6R $\alpha$  or IL6-sIL-6R $\alpha$  (hyper-IL-6).

(B) Same as in (A), except that animals were first immunized with lipid A adjuvant and spleen was harvested 3 days later.

(legend continued on next page)

component) accounted for a minor fraction of circulating sIL-6R (Figure S3C) and that antibody responses were not affected in *Batf3*<sup>-/-</sup> (Figure S3D).

### IL-6 *trans* signaling through cDC-derived sIL-6R naturally adjuvants humoral responses by promoting differentiation to plasma cells *in vivo*

B cells are limited in surface gp130, which is needed for IL-6 *trans* signaling (Larousserie et al., 2006). We found that gp130 increased upon B cell differentiation to plasmablasts and verified that these cells are specifically receptive to IL-6 *trans* signaling, as measured by induction of STAT3 phosphorylation by IL-6-sIL-6R $\alpha$  (hyper-IL6) (Fischer et al., 1997; Xu et al., 2017; Figures 3A–3D). The number of plasmablasts could be increased by pre-immunizing with our lipid A adjuvant (3 days post vaccination; Figures 3B and 3D). To define the significance of IL-6 *trans* signaling *in vivo*, we repeated our immunization regimen containing the lipid A adjuvant and measured plasmablast differentiation to plasma cells 1 week post vaccination. We found that differentiation was attenuated in cDC-*IL6ra*<sup>-/-</sup> but partially restored by injection of recombinant sIL-6R (Figure 3E). cDC-*Irf5*<sup>-/-</sup> mice showed no defect compared with wild-type (WT) animals. Collectively, this reveals a natural B cell-adjuvating activity of cDC-derived sIL-6R (Figure 3F).

### cDCs regulate TLR4-dependent induction of sIL-6R release and serum persistence of IL-6 following bacterial immune stimulation

sIL6R and sgp130 are proposed to form a biological buffer system that regulates IL-6 half-life in blood (Rose-John, 2012, 2017; Scheller and Rose-John, 2012), but this has not been demonstrated experimentally *in vivo* (Baran et al., 2018). To evaluate this, we intravenously injected our transgenic animals with bacterial lipid A to mimic sepsis and then tracked the pharmacokinetics of IL-6 release and capture in the bloodstream (Figure 4A). After injection, sIL-6R concentration became elevated and then declined in WT and cDC-*Irf5*<sup>-/-</sup> mice but remained low and did not change in cDC-*IL6ra*<sup>-/-</sup> (Figure 4A). Induction of sIL-6R release did not occur in *Tlr4*<sup>-/-</sup>, but these animals retained a normal sIL-6R set point. Free IL-6, induced by lipid A exposure, was only detectable in cDC-*IL6ra*<sup>-/-</sup>, where it showed delayed clearance (Figure 4A). Similar dysregulation was seen in *Zbtb46*-DTR chimeras (Figure 4B). Restoration of serum sIL-6R in cDC-*IL6ra*<sup>-/-</sup> via gene delivery by adeno-associated virus (AAV) largely rescued IL-6 capture after inoculating with bacterial lipid A (Figure S4A). In contrast to bacterial lipopolysaccharide (LPS), IL-6 treatment alone did not stimulate sIL-6R release, as evaluated in bone marrow-derived DCs (BMDCs) (Figure 4C).

### cDCs regulate TLR7-dependent induction of sIL-6R biogenesis and serum persistence of IL-6 following infection with influenza virus

We infected WT, *Tlr4*<sup>-/-</sup>, *Tlr7*<sup>-/-</sup>, and cDC-*IL6ra*<sup>-/-</sup> mice with New Caledonia/20/1999 (NC99), an H1N1 virus that propagates but does not cause disease in mice (Amitai et al., 2020; Glaser et al., 2007; Sangesland et al., 2019). We observed induction of sIL-6R release in all genotypes except *Tlr7*<sup>-/-</sup> and cDC-*IL6ra*<sup>-/-</sup>, where TLR7 recognizes influenza viral RNA (Lund et al., 2004). Influenza virus is also a strong inducer of IL-6 release (Dutta et al., 2013; Vogel et al., 2014), and we found that downstream capture of the released IL-6 was dysregulated in cDC-*IL6ra*<sup>-/-</sup> (Figure 4D). This buffer activity was rescued by AAV-mediated restoration of sIL-6R (Figure S4B).

We next performed the same AAV-mediated rescue of sIL-6R in a severe model of infection. Animals received a lethal dose of A/Puerto Rico/8/34 (PR8) influenza virus in which lung disease is accompanied by cytokine storming (Dutta et al., 2013; Vogel et al., 2014). We found that restoration of sIL-6R significantly slowed the morbidity rate, as measured by daily weight loss (Figure S4C).

### Induction of sIL-6R release, but not the set point, is regulated by cDC-ADAM17

Induction of sIL-6R release following immune stimulation is needed to generate molar excess relative to sgp130 to enable IL-6 *trans* signaling and pro-inflammatory reactions (Rose-John, 2012, 2017; Scheller and Rose-John, 2012; Tanaka et al., 2014). The cell surface sheddase ADAM17 has been implicated in sIL-6R release from BMDC following incubation with LPS *in vitro* (Garbers et al., 2011). We found that induction of sIL-6R release *in vivo* was significantly blunted in cDC-*Adam17*<sup>-/-</sup> mice following inoculation with bacterial lipid A and after infection with influenza virus (Figures 4E and 4F). Notably, the sIL-6R set point was unaffected in cDC-*Adam17*<sup>-/-</sup>, suggesting that the set point and immune-stimulated release rely on different mechanisms (Figure 4G).

## DISCUSSION

The textbook model of humoral immunity predicts that cDC removal should only reduce T cell-dependent antibody responses because of lack of DC-primed T cell help (Adler et al., 2017; Andersen et al., 2019; O et al., 2014). However, we found that co-reduction in TCR-independent IgM output was a general property of TD antigens. Reduced IgM responses have also been seen in *Igax*-DTR chimeras (Gonzalez et al., 2010) but have not been explained. This defect appears to be reversible because longer-term exposure to DT in *Zbtb46*-DTR chimeras (18 weeks)


(C) Quantification of the data in (A). Signaling induced within gate I and gate II was measured as the percentage of STAT3-activated cells (sIL-6R $\alpha$ -stimulated minus unstimulated and IL-6-sIL-6R $\alpha$ -stimulated minus unstimulated; mean  $\pm$  SD, n = 4 animals per group, \*\*\*p < 0.001, Student's t test).

(D) Quantification of the data in (B) (as in C).

(E) Differentiation from plasmablasts (CD3<sup>-</sup>/B220<sup>lo</sup>/CD138<sup>+</sup>/MHCII<sup>+</sup>) to plasma cells (CD3<sup>-</sup>/B220<sup>lo</sup>/CD138<sup>+</sup>/MHC class II<sup>o</sup>/CD93<sup>+</sup>) was monitored within each genotype 1 week post-immunization with lipid A adjuvant, and cDC-*IL6ra*<sup>-/-</sup> mice were also co-injected with recombinant sIL-6R (as in Figure 2E). The proportion of plasmablasts differentiating into plasma cells (indicated by a box in flow plots) was then quantified below (mean  $\pm$  SD, n = 3 animals per group; \*\*p < 0.005, ANOVA with Tukey's test).

(F) Model for T cell-independent, cDC-dependent control over antibody responses.





(legend on next page)

fails to sustain cDC depletion, and anti-DT immunoglobulin becomes detectable (Rombouts et al., 2017). We demonstrated that the cDC-dependent IgM response could be functionally rescued within our 2-week DT exposure period when non-depleted cDCs were present in the MHC class II-deficient background. We therefore applied this IgM response as a functional readout to identify cDC-dependent but T cell-independent factors regulating humoral immunity.

DCs have long been demonstrated to directly prime B cells through antigen uptake and display (Balázs et al., 2002; Bergtold et al., 2005; Chappell et al., 2012; MacLennan and Vinuesa, 2002; Qi et al., 2006). However, we found that antigen uptake into the spleen was unaffected following cDC depletion, suggesting that other factors may also be in operation. Notably, genetic depletion of IL-6 and its master regulator IRF5 (Takaoka et al., 2005) recapitulated the IgM response defect. Although independent of IFNAR, the phenotype could be partially rescued by recombinant IL-6, a known promoter of humoral reactions (Dubois et al., 1998; Karnowski et al., 2012; Tanaka et al., 2014). A previous study has shown that loss of IL-6 function in a mouse model of rheumatoid arthritis could only be fully rescued by injection of hyper-IL-6 (Nowell et al., 2003). Because our inoculum contained bacterial lipid A adjuvant, a potent inducer of IL-6 release (Matsuura et al., 1999; Wang et al., 1991), we hypothesized that cDCs could modulate such IL-6-dependent effects through IL-6 production and/or by manipulating access to IL-6R. Our transgenic mice suggested that the latter was true, where cDC-*IL6ra*<sup>-/-</sup> recapitulated the IgM response deficit. This was not seen in cDC-*Irf5*<sup>-/-</sup>, suggesting that cDC production of IL-6, which is not needed for systemic IL-6 release (Heink et al., 2017), was also not required here. Notably, circulating sIL-6R was strongly reduced in cDC-*IL6ra*<sup>-/-</sup>, and injecting sIL-6R partially restored IgM and IgG output. This does not preclude a role of cDC-IL-6R (Heink et al., 2017) but strongly implicates cDC-derived sIL-6R in gating IL-6-dependent and T cell-independent control over B cell priming. B cells are limited in surface gp130 (Larousserie et al., 2006), but we found that gp130 was elevated in plasmablasts, rendering these cells receptive to IL-6 *trans* signaling. Moreover, addition of recombinant sIL-6R to partially restored defective plasma cell differentiation in cDC-*IL6ra*<sup>-/-</sup> mice. These findings unveil a cDC-governed pathway for naturally adjuvating antibody responses through IL-6 *trans* signaling.

Our results also demonstrate that cDCs regulate the concentration of sIL-6R in blood. *Zbtb46* is also expressed by endothelial cells (Satpathy et al., 2012a), but these cells do not express IL-6R (Romano et al., 1997), and our *Zbtb46*-DTR chimeras confirmed cDC-dependent sIL-6R reduction when the endothelium was unaltered. Our orthogonal analyses of *Batf3*<sup>-/-</sup>, which are depleted in cDC1 (minority cDCs) but preserve cDC2 (majority cDCs) (Hildner et al., 2008), suggest an additive contribution to the sIL-6R in circulation.

Induction of sIL-6R release, as stimulated by diverse immune challenges, was also cDC dependent. This additional sIL-6R release underscores the proinflammatory state and is needed to bring sIL-6R to molar excess over sgp130 and enable IL-6 *trans* signaling (Rose-John, 2012, 2017; Scheller and Rose-John, 2012). We found that immune release of sIL-6R after inoculation with bacterial lipid A or after influenza viral infection required ligation of the appropriate innate immune receptor followed by cDC-dependent sIL-6R production. The latter step relied on sheddase activity by ADAM17, consistent with studies on BMDCs *in vitro* (Garbers et al., 2011; Schumacher et al., 2015). Notably, the sIL-6R set point was not dependent on cDC-ADAM17, suggesting that set point and induction are regulated by distinct pathways, perhaps involving multiple sheddases and/or vesicular release mechanisms (Garbers et al., 2011; Schumacher et al., 2015, 2016). Our results do not preclude production of sIL-6R by non-cDC cell types, and cDC contribution to sIL-6R set point is likely included when assessed with *lyz2-cre* (McFarland-Mancini et al., 2010; Shi et al., 2018).

Although IL-6 release is an immunodefensive action, inflammatory disorders and cytokine storms are often marked by hyper-elevated concentrations of this cytokine (Narazaki et al., 2017; Tanaka et al., 2016, 2018) and can signify terminal states, as in COVID-19 (McElvaney et al., 2020; Mehta et al., 2020). Defects in the human IL-6R gene are also linked to elevated IL-6 (Spencer et al., 2019). We experimentally demonstrated that cDC-derived sIL-6R regulates the concentration of free IL-6 in blood. IL-6 showed delayed clearance when cDC-derived sIL-6R was lacking, and restoration of sIL-6R rescued in-solution capture of IL-6 in our bacterial and virus challenge models. Restoration of sIL-6R also slowed morbidity after lethal influenza viral challenge, where respiratory distress is underscored by cytokine storming (Dutta

#### Figure 4. cDCs regulate the systemic sIL-6R set point and induction of release, regulating the pharmacokinetics of free IL-6 generated in response to diverse immune challenges

(A) Animals were injected intravenously with bacterial lipid A to mimic sepsis and promote IL-6 release. Serum concentrations of sIL-6R and IL-6 were measured in WT, cDC-*Irf5*<sup>-/-</sup>, *Tlr4*<sup>-/-</sup>, and cDC-*IL6ra*<sup>-/-</sup> (mean ± SD; \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, ANOVA with Tukey's test; n = 3 per group).

(B) sIL-6R and IL-6 serum concentrations during the same time course in *Zbtb46*-DTR chimeras receiving and not receiving DT (mean ± SD; \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, ANOVA with Tukey's test; n = 3 per group).

(C) BMDCs were cultured and exposed to recombinant IL-6 or bacterial LPS, and sIL-6R was measured in the supernatant (mean SD; \*\*\*\*p < 0.0001, ANOVA with Tukey's test).

(D) Animals were infected with a sublethal dose of NC99 influenza virus, and serum sIL-6R and IL-6 concentrations were measured in WT, *Tlr4*<sup>-/-</sup>, *Tlr7*<sup>-/-</sup>, and cDC-*IL6ra*<sup>-/-</sup> (mean ± SD; \*p < 0.05, \*\*\*p < 0.001, ANOVA with Tukey's test; n = 3 per group). In bacterial and viral challenge models, the defect in IL-6 capture within cDC-*IL6ra*<sup>-/-</sup> was rescued by restoring sIL-6R using AAV gene delivery (Figures S4A and S4B). Restoration of sIL-6R also reduced the morbidity rate after lethal challenge with influenza virus (Figure S4C).

(E and F) cDC-*Adam17*<sup>-/-</sup> had no defect in the sIL-6R set point but significantly blunted sIL-6R release following stimulation with bacterial lipid A (E) or infection with influenza virus (F) (mean ± SD; \*p < 0.04, \*\*p < 0.01, F test for slope comparison; n = 5 per group).

(G) Regulating free IL-6 and IL-6 *trans* signaling via cDC-derived sIL-6R.

Please also see Figure S4.

et al., 2013; Vogel et al., 2014). Regulating the in-solution persistence of IL-6 will also be reliant on sgp130, where our results reinforce the view that sIL-6R is a buffering agent that guards against systemic IL-6 signaling (Rose-John, 2012, 2017; Scheller and Rose-John, 2012; Tanaka et al., 2016). IL-6 buffering may also have general therapeutic properties: a SNP in human IL-6R enhances ADAM17 sheddase activity *in vitro* (Müllberg et al., 1994), is matched with higher sIL-6R serum concentration *in vivo*, and is associated with reduced risk of congestive heart disease, atrial fibrillation, abdominal aortic aneurism, and rheumatoid arthritis (Sarwar et al., 2012; Ferreira et al., 2013; Interleukin-6 Receptor Mendelian Randomization Analysis (IL6R MR) Consortium et al., 2012; Scheller and Rose-John, 2012).

### Limitations of Study

Our conclusions rely on *Zbtb46* expression as a specific marker of cDCs in mice (Diao et al., 2018; Durai and Murphy, 2016; Loschko et al., 2016a, 2016b; Lu et al., 2017; Macdougall et al., 2018; Meredith et al., 2012; Rombouts et al., 2017; Satpathy et al., 2012a, 2012b; Sun et al., 2017; Zhang et al., 2019). There is no comparable marker for human cDCs, and the contribution of this immune cell lineage to serum sIL-6R in humans remains unclear. Nevertheless, our finding that sIL-6R serves to buffer the in-solution persistence of free IL-6 will be independent of the cellular source of sIL-6R.

### STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Transgenic mice
  - Bone marrow chimeras
  - Splenectomized mice
- METHOD DETAILS
  - Protein antigens
  - Immunization regimens
  - ELISA
  - Imaging antigen uptake by immunofluorescence
  - Isolation of splenocytes and flow cytometry
  - FACS and immunoblotting
  - B cell stimulation *in vitro*
  - Simulation of bone marrow-derived dendritic cells *in vitro*
  - AAV sIL6R production
  - Bacterial and viral immune challenges
- QUANTIFICATION AND STATISTICAL ANALYSIS

### SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.immuni.2020.12.001>.

### ACKNOWLEDGMENTS

D.L. was supported by NIH grants (R01AI137057, DP2DA042422, R01AI124378, and R01AI153098), the Harvard University Milton Award, and the Gilead Research Scholars Program. H.C.R. was supported by the NIH (DK068181, AI113333, DK043351, and GM138599). We thank Lingwood lab technicians past and present for generating the recombinant protein antigens used in this study (Grant Weaver, Rina Villar, Celina Keating, Matthew Smoot, Julia Bals, and Vintus Okonkwo). The authors also thank Masaru Kanekiyo, Jose Ordovas-Montanes, Shiv Pillai, Facundo Batista, Ulrich von Andrian, and Lingwood lab members for helpful discussions. We gratefully acknowledge Michal Grzybek for assistance with figure graphics and Thomas Diefenbach for help with microscopy and imaging analyses.

### AUTHOR CONTRIBUTIONS

A.S.Y., H.-C.R., A.B.B., and D.L. designed the research. A.S.Y., L.R., P.S., T.O., and V.D.V. performed the research. M.S., T.B.M., and E.C.L. provided reagents. A.S.Y. and D.L. analyzed the data and wrote the paper.

### DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: April 6, 2020

Revised: October 17, 2020

Accepted: December 2, 2020

Published: December 22, 2020

### REFERENCES

- Adler, L.N., Jiang, W., Bhamidipati, K., Millican, M., Macaubas, C., Hung, S.C., and Mellins, E.D. (2017). The Other Function: Class II-Restricted Antigen Presentation by B Cells. *Front. Immunol.* 8, 319.
- Altman, M.O., Angeletti, D., and Yewdell, J.W. (2018). Antibody Immunodominance: The Key to Understanding Influenza Virus Antigenic Drift. *Viral Immunol.* 31, 142–149.
- Alvarez, D., Vollmann, E.H., and von Andrian, U.H. (2008). Mechanisms and consequences of dendritic cell migration. *Immunity* 29, 325–342.
- Amitai, A., Sangesland, M., Barnes, R.M., Rohrer, D., Lonberg, N., Lingwood, D., and Chakraborty, A.K. (2020). Defining and Manipulating B Cell Immunodominance Hierarchies to Elicit Broadly Neutralizing Antibody Responses against Influenza Virus. *Cell Syst.* Published online May 18, 2020. <https://doi.org/10.2139/ssrn.3586996>.
- Andersen, T.K., Huszthy, P.C., Gopalakrishnan, R.P., Jacobsen, J.T., Fauskanger, M., Tveita, A.A., Grødeland, G., and Bogen, B. (2019). Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules. *NPJ Vaccines* 4, 9.
- Angeletti, D., Gibbs, J.S., Angel, M., Kosik, I., Hickman, H.D., Frank, G.M., Das, S.R., Wheatley, A.K., Prabhakaran, M., Leggat, D.J., et al. (2017). Defining B cell immunodominance to viruses. *Nat. Immunol.* 18, 456–463.
- Balazs, A.B., Bloom, J.D., Hong, C.M., Rao, D.S., and Baltimore, D. (2013). Broad protection against influenza infection by vectored immunoprophylaxis in mice. *Nat. Biotechnol.* 31, 647–652.
- Balazs, A.B., Chen, J., Hong, C.M., Rao, D.S., Yang, L., and Baltimore, D. (2011). Antibody-based protection against HIV infection by vectored immunoprophylaxis. *Nature* 481, 81–84.
- Balázs, M., Martin, F., Zhou, T., and Kearney, J. (2002). Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. *Immunity* 17, 341–352.
- Baran, P., Hansen, S., Waetzig, G.H., Akbarzadeh, M., Lamertz, L., Huber, H.J., Ahmadian, M.R., Moll, J.M., and Scheller, J. (2018). The balance of interleukin (IL)-6, IL-6 soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling. *J. Biol. Chem.* 293, 6762–6775.

- Bergtold, A., Desai, D.D., Gavhane, A., and Clynes, R. (2005). Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. *Immunity* 23, 503–514.
- Biran, N., Ip, A., Ahn, J., Go, R.C., Wang, S., Mathura, S., Sinclair, B.A., Bednarz, U., Marafelias, M., Hansen, E., et al. (2020). Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. *Lancet Rheumatol.* 2, e603–e612.
- Chalaris, A., Rabe, B., Paliga, K., Lange, H., Laskay, T., Fielding, C.A., Jones, S.A., Rose-John, S., and Scheller, J. (2007). Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. *Blood* 110, 1748–1755.
- Chappell, C.P., Draves, K.E., Giltiay, N.V., and Clark, E.A. (2012). Extrafollicular B cell activation by marginal zone dendritic cells drives T cell-dependent antibody responses. *J. Exp. Med.* 209, 1825–1840.
- Diao, J., Gu, H., Tang, M., Zhao, J., and Catral, M.S. (2018). Tumor Dendritic Cells (DCs) Derived from Precursors of Conventional DCs Are Dispensable for Intratumor CTL Responses. *J. Immunol.* 201, 1306–1314.
- Doganci, A., Eigenbrod, T., Krug, N., De Sanctis, G.T., Hausding, M., Erpenbeck, V.J., Haddad, B., Lehr, H.A., Schmitt, E., Bopp, T., et al. (2005). The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. *J. Clin. Invest.* 115, 313–325.
- Dubois, B., Massacrier, C., Vanbervliet, B., Fayette, J., Brière, F., Banchereau, J., and Caux, C. (1998). Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. *J. Immunol.* 161, 2223–2231.
- Durai, V., and Murphy, K.M. (2016). Functions of Murine Dendritic Cells. *Immunity* 45, 719–736.
- Dutta, A., Miaw, S.C., Yu, J.S., Chen, T.C., Lin, C.Y., Lin, Y.C., Chang, C.S., He, Y.C., Chuang, S.H., Yen, M.I., and Huang, C.T. (2013). Altered T-bet dominance in IFN- $\gamma$ -decoupled CD4+ T cells with attenuated cytokine storm and preserved memory in influenza. *J. Immunol.* 190, 4205–4214.
- Fazel Modares, N., Polz, R., Haghighi, F., Lamertz, L., Behnke, K., Zhuang, Y., Kordes, C., Häussinger, D., Sorg, U.R., Pfeffer, K., et al. (2019). IL-6 Trans-signaling Controls Liver Regeneration After Partial Hepatectomy. *Hepatology* 70, 2075–2091.
- Ferreira, R.C., Freitag, D.F., Cutler, A.J., Howson, J.M., Rainbow, D.B., Smyth, D.J., Kaptoge, S., Clarke, P., Boreham, C., Coulson, R.M., et al. (2013). Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. *PLoS Genet.* 9, e1003444.
- Fischer, M., Goldschmitt, J., Peschel, C., Brakenhoff, J.P., Kallen, K.J., Wollmer, A., Grötzing, J., and Rose-John, S. (1997). I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. *Nat. Biotechnol.* 15, 142–145.
- Galanos, C., Freudenberg, M.A., and Reutter, W. (1979). Galactosamine-induced sensitization to the lethal effects of endotoxin. *Proc. Natl. Acad. Sci. USA* 76, 5939–5943.
- Garbers, C., Jänner, N., Chalaris, A., Moss, M.L., Floss, D.M., Meyer, D., Koch-Nolte, F., Rose-John, S., and Scheller, J. (2011). Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. *J. Biol. Chem.* 286, 14804–14811.
- Garbers, C., Monhasery, N., Aparicio-Siegmund, S., Lokau, J., Baran, P., Nowell, M.A., Jones, S.A., Rose-John, S., and Scheller, J. (2014). The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. *Biochim. Biophys. Acta* 1842, 1485–1494.
- Glaser, L., Conenello, G., Paulson, J., and Palese, P. (2007). Effective replication of human influenza viruses in mice lacking a major alpha2,6 sialyltransferase. *Virus Res.* 126, 9–18.
- Gonzalez, S.F., Lukacs-Kornek, V., Kuligowski, M.P., Pitcher, L.A., Degen, S.E., Kim, Y.A., Cloninger, M.J., Martinez-Pomares, L., Gordon, S., Turley, S.J., and Carroll, M.C. (2010). Capture of influenza by medullary dendritic cells via SIGN-R1 is essential for humoral immunity in draining lymph nodes. *Nat. Immunol.* 11, 427–434.
- Heink, S., Yogev, N., Garbers, C., Herwerth, M., Aly, L., Gasperi, C., Husterer, V., Croxford, A.L., Möller-Hackbarth, K., Bartsch, H.S., et al. (2017). Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. *Nat. Immunol.* 18, 74–85.
- Henrickson, S.E., Perro, M., Loughhead, S.M., Senman, B., Stutte, S., Quigley, M., Alexe, G., Iannacone, M., Flynn, M.P., Omid, S., et al. (2013). Antigen availability determines CD8+ T cell-dendritic cell interaction kinetics and memory fate decisions. *Immunity* 39, 496–507.
- Hildner, K., Edelson, B.T., Purtha, W.E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B.U., Unanue, E.R., Diamond, M.S., et al. (2008). Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. *Science* 322, 1097–1100.
- Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow, D.J., Holmes, M.V., Kuchenbaecker, K.B., Engmann, J.E., Shah, T., Sofat, R., Guo, Y., Chung, C., Peasey, A., et al. (2012). The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. *Lancet* 379, 1214–1224.
- Jostock, T., Mullberg, J., Ozbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M.F., and Rose-John, S. (2001). Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. *Eur. J. Biochem.* 268, 160–167.
- Kanekiyo, M., Wei, C.J., Yassine, H.M., McTamney, P.M., Boyington, J.C., Whittle, J.R., Rao, S.S., Kong, W.P., Wang, L., and Nabel, G.J. (2013). Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. *Nature* 499, 102–106.
- Karnowski, A., Chevrier, S., Belz, G.T., Mount, A., Emslie, D., D'Costa, K., Tarlinton, D.M., Kallies, A., and Corcoran, L.M. (2012). B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1. *J. Exp. Med.* 209, 2049–2064.
- Kim, S.J., Caton, M., Wang, C., Khalil, M., Zhou, Z.J., Hardin, J., and Diamond, B. (2008). Increased IL-12 inhibits B cells' differentiation to germinal center cells and promotes differentiation to short-lived plasmablasts. *J. Exp. Med.* 205, 2437–2448.
- Kishimoto, T. (2010). IL-6: from its discovery to clinical applications. *Int. Immunol.* 22, 347–352.
- Larousserie, F., Charlot, P., Bardel, E., Froger, J., Kastelein, R.A., and Devergne, O. (2006). Differential effects of IL-27 on human B cell subsets. *J. Immunol.* 176, 5890–5897.
- Loschko, J., Rieke, G.J., Schreiber, H.A., Meredith, M.M., Yao, K.H., Guernonprez, P., and Nussenzweig, M.C. (2016a). Inducible targeting of cDCs and their subsets in vivo. *J. Immunol. Methods* 434, 32–38.
- Loschko, J., Schreiber, H.A., Rieke, G.J., Esterházy, D., Meredith, M.M., Pedicord, V.A., Yao, K.H., Caballero, S., Pamer, E.G., Mucida, D., and Nussenzweig, M.C. (2016b). Absence of MHC class II on cDCs results in microbial-dependent intestinal inflammation. *J. Exp. Med.* 213, 517–534.
- Lu, E., Dang, E.V., McDonald, J.G., and Cyster, J.G. (2017). Distinct oxysterol requirements for positioning naïve and activated dendritic cells in the spleen. *Sci. Immunol.* 2, eaal5237.
- Lund, J.M., Alexopoulou, L., Sato, A., Karow, M., Adams, N.C., Gale, N.W., Iwasaki, A., and Flavell, R.A. (2004). Recognition of single-stranded RNA viruses by Toll-like receptor 7. *Proc. Natl. Acad. Sci. USA* 101, 5598–5603.
- Maccougall, C.E., Wood, E.G., Loschko, J., Scagliotti, V., Cassidy, F.C., Robinson, M.E., Feldhahn, N., Castellano, L., Voisin, M.B., Marelli-Berg, F., et al. (2018). Visceral Adipose Tissue Immune Homeostasis Is Regulated by the Crosstalk between Adipocytes and Dendritic Cell Subsets. *Cell Metab.* 27, 588–601.e4.
- MacLennan, I., and Vinuesa, C. (2002). Dendritic cells, BAFF, and APRIL: innate players in adaptive antibody responses. *Immunity* 17, 235–238.
- Matsuura, M., Kiso, M., and Hasegawa, A. (1999). Activity of monosaccharide lipid A analogues in human monocytic cells as agonists or antagonists of bacterial lipopolysaccharide. *Infect. Immun.* 67, 6286–6292.
- Matthews, V., Schuster, B., Schütze, S., Bussmeyer, I., Ludwig, A., Hundhausen, C., Sadowski, T., Saftig, P., Hartmann, D., Kallen, K.J., and Rose-John, S. (2003). Cellular cholesterol depletion triggers shedding of the



- human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). *J. Biol. Chem.* **278**, 38829–38839.
- McElvaney, O.J., Hobbs, B.D., Qiao, D., McElvaney, O.F., Moll, M., McEvoy, N.L., Clarke, J., O'Connor, E., Walsh, S., Cho, M.H., et al. (2020). A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. *EBioMedicine* **61**, 103026.
- McFarland-Mancini, M.M., Funk, H.M., Paluch, A.M., Zhou, M., Giridhar, P.V., Mercer, C.A., Kozma, S.C., and Drew, A.F. (2010). Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. *J. Immunol.* **184**, 7219–7228.
- Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., and Manson, J.J.; HLH Across Speciality Collaboration, UK (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* **395**, 1033–1034.
- Meredith, M.M., Liu, K., Darrasse-Jeze, G., Kamphorst, A.O., Schreiber, H.A., Guermonprez, P., Idoyaga, J., Cheong, C., Yao, K.H., Niec, R.E., and Nussenzweig, M.C. (2012). Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. *J. Exp. Med.* **209**, 1153–1165.
- Müllberg, J., Durie, F.H., Otten-Evans, C., Alderson, M.R., Rose-John, S., Cosman, D., Black, R.A., and Mohler, K.M. (1995). A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. *J. Immunol.* **155**, 5198–5205.
- Müllberg, J., Oberthür, W., Lottspeich, F., Mehl, E., Dittrich, E., Graeve, L., Heinrich, P.C., and Rose-John, S. (1994). The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. *J. Immunol.* **152**, 4958–4968.
- Narazaki, M., Tanaka, T., and Kishimoto, T. (2017). The role and therapeutic targeting of IL-6 in rheumatoid arthritis. *Expert Rev. Clin. Immunol.* **13**, 535–551.
- Nowell, M.A., Richards, P.J., Horiuchi, S., Yamamoto, N., Rose-John, S., Topley, N., Williams, A.S., and Jones, S.A. (2003). Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. *J. Immunol.* **171**, 3202–3209.
- O, E., Lee, Y.T., Ko, E.J., Kim, K.H., Lee, Y.N., Song, J.M., Kwon, Y.M., Kim, M.C., Perez, D.R., and Kang, S.M. (2014). Roles of major histocompatibility complex class II in inducing protective immune responses to influenza vaccination. *J. Virol.* **88**, 7764–7775.
- Park, S.M., Omatsu, T., Zhao, Y., Yoshida, N., Shah, P., Zagani, R., and Reinecker, H.C. (2019). T cell fate following *Salmonella* infection is determined by a STING-IRF1 signaling axis in mice. *Commun. Biol.* **2**, 464.
- Qi, H., Egen, J.G., Huang, A.Y., and Germain, R.N. (2006). Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. *Science* **312**, 1672–1676.
- Riethmueller, S., Ehlers, J.C., Lokau, J., Düsterhöft, S., Knittler, K., Dombrowsky, G., Grötzinger, J., Rabe, B., Rose-John, S., and Garbers, C. (2016). Cleavage Site Localization Differentially Controls Interleukin-6 Receptor Proteolysis by ADAM10 and ADAM17. *Sci. Rep.* **6**, 25550.
- Romano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P., Ghezzi, P., Faggioni, R., Luini, W., van Hinsbergh, V., Sozzani, S., et al. (1997). Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. *Immunity* **6**, 315–325.
- Rombouts, M., Cools, N., Grootaert, M.O., de Bakker, F., Van Brussel, I., Wouters, A., De Meyer, G.R., De Winter, B.Y., and Schrijvers, D.M. (2017). Long-Term Depletion of Conventional Dendritic Cells Cannot Be Maintained in an Atherosclerotic Zbtb46-DTR Mouse Model. *PLoS ONE* **12**, e0169608.
- Rose-John, S. (2012). IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. *Int. J. Biol. Sci.* **8**, 1237–1247.
- Rose-John, S. (2017). The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation. *Clin. Pharmacol. Ther.* **102**, 591–598.
- Rubtsov, A., Strauch, P., Digiacomo, A., Hu, J., Pelanda, R., and Torres, R.M. (2005). Lsc regulates marginal-zone B cell migration and adhesion and is required for the IgM T-dependent antibody response. *Immunity* **23**, 527–538.
- Sangesland, M., Ronsard, L., Kazer, S.W., Bals, J., Boyoglu-Barnum, S., Yousif, A.S., Barnes, R., Feldman, J., Quirindongo-Crespo, M., McTamney, P.M., et al. (2019). Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus. *Immunity* **51**, 735–749.e8.
- Sangesland, M., Yousif, A.S., Ronsard, L., Kazer, S.W., Zhu, A.L., Gatter, G.J., Hayward, M.R., Barnes, R.M., Quirindongo-Crespo, M., Rohrer, D., et al. (2020). A Single Human V<sub>H</sub>-gene Allows for a Broad-Spectrum Antibody Response Targeting Bacterial Lipopolysaccharides in the Blood. *Cell Rep.* **32**, 108065.
- Sarwar, N., Butterworth, A.S., Freitag, D.F., Gregson, J., Willeit, P., Gorman, D.N., Gao, P., Saleheen, D., Rendon, A., Nelson, C.P., et al.; IL6R Genetics Consortium Emerging Risk Factors Collaboration (2012). Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. *Lancet* **379**, 1205–1213.
- Satpathy, A.T., Kc, W., Albring, J.C., Edelson, B.T., Kretzer, N.M., Bhattacharya, D., Murphy, T.L., and Murphy, K.M. (2012a). Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages. *J. Exp. Med.* **209**, 1135–1152.
- Satpathy, A.T., Wu, X., Albring, J.C., and Murphy, K.M. (2012b). Re(de)fining the dendritic cell lineage. *Nat. Immunol.* **13**, 1145–1154.
- Scheller, J., Ohnesorge, N., and Rose-John, S. (2006). Interleukin-6 trans-signaling in chronic inflammation and cancer. *Scand. J. Immunol.* **63**, 321–329.
- Scheller, J., and Rose-John, S. (2012). The interleukin 6 pathway and atherosclerosis. *Lancet* **380**, 338.
- Schuetz, H., Oestreich, R., Waetzig, G.H., Annema, W., Luchtfeld, M., Hillmer, A., Bavendiek, U., von Felden, J., Divchev, D., Kempf, T., et al. (2012). Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. *Arterioscler. Thromb. Vasc. Biol.* **32**, 281–290.
- Schumacher, N., Meyer, D., Mauermann, A., von der Heyde, J., Wolf, J., Schwarz, J., Knittler, K., Murphy, G., Michalek, M., Garbers, C., et al. (2015). Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles. *J. Biol. Chem.* **290**, 26059–26071.
- Schumacher, N., Schmidt, S., Schwarz, J., Dohr, D., Lokau, J., Scheller, J., Garbers, C., Chalaris, A., Rose-John, S., and Rabe, B. (2016). Circulating Soluble IL-6R but Not ADAM17 Activation Drives Mononuclear Cell Migration in Tissue Inflammation. *J. Immunol.* **197**, 3705–3715.
- Shi, J., Hua, L., Harmer, D., Li, P., and Ren, G. (2018). Cre Driver Mice Targeting Macrophages. *Methods Mol. Biol.* **1784**, 263–275.
- Somers, E.C., Eschenauer, G.A., Troost, J.P., Golob, J.L., Gandhi, T.N., Wang, L., Zhou, N., Petty, L.A., Baang, J.H., Dillman, N.O., et al. (2020). Tocilizumab for treatment of mechanically ventilated patients with COVID-19. *Clin. Infect. Dis.* Published online July 11, 2020. <https://doi.org/10.1093/cid/ciaa954>.
- Song, H., and Cerny, J. (2003). Functional heterogeneity of marginal zone B cells revealed by their ability to generate both early antibody-forming cells and germinal centers with hypermutation and memory in response to a T-dependent antigen. *J. Exp. Med.* **198**, 1923–1935.
- Spencer, S., Köstel Bal, S., Egner, W., Lango Allen, H., Raza, S.I., Ma, C.A., Gürel, M., Zhang, Y., Sun, G., Sabroe, R.A., et al. (2019). Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. *J. Exp. Med.* **216**, 1986–1998.
- Stebegg, M., Bignon, A., Hill, D.L., Silva-Cayetano, A., Krueger, C., Vanderleyden, I., Innocentin, S., Boon, L., Wang, J., Zand, M.S., et al. (2020). Rejuvenating conventional dendritic cells and T follicular helper cell formation after vaccination. *eLife* **9**, e52473.
- Sun, T., Rojas, O.L., Li, C., Ward, L.A., Philpott, D.J., and Gommerman, J.L. (2017). Intestinal Batf3-dependent dendritic cells are required for optimal antiviral T-cell responses in adult and neonatal mice. *Mucosal Immunol.* **10**, 775–788.
- Takaoka, A., Yanai, H., Kondo, S., Duncan, G., Negishi, H., Mizutani, T., Kano, S., Honda, K., Ohba, Y., Mak, T.W., and Taniguchi, T. (2005). Integral role of



- IRF-5 in the gene induction programme activated by Toll-like receptors. *Nature* 434, 243–249.
- Tanaka, T., Narazaki, M., and Kishimoto, T. (2014). IL-6 in inflammation, immunity, and disease. *Cold Spring Harb. Perspect. Biol.* 6, a016295.
- Tanaka, T., Narazaki, M., and Kishimoto, T. (2016). Immunotherapeutic implications of IL-6 blockade for cytokine storm. *Immunotherapy* 8, 959–970.
- Tanaka, T., Narazaki, M., and Kishimoto, T. (2018). Interleukin (IL-6) Immunotherapy. *Cold Spring Harb. Perspect. Biol.* 10, a028456.
- Tenhumberg, S., Waetzig, G.H., Chalaris, A., Rabe, B., Seegert, D., Scheller, J., Rose-John, S., and Grötzinger, J. (2008). Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. *J. Biol. Chem.* 283, 27200–27207.
- Tesfaye, D.Y., Gudjonsson, A., Bogen, B., and Fossum, E. (2019). Targeting Conventional Dendritic Cells to Fine-Tune Antibody Responses. *Front. Immunol.* 10, 1529.
- Vogel, A.J., Harris, S., Marsteller, N., Condon, S.A., and Brown, D.M. (2014). Early cytokine dysregulation and viral replication are associated with mortality during lethal influenza infection. *Viral Immunol.* 27, 214–224.
- Vollmer, P., Walev, I., Rose-John, S., and Bhakdi, S. (1996). Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor. *Infect. Immun.* 64, 3646–3651.
- Wang, M.H., Flad, H.D., Feist, W., Brade, H., Kusumoto, S., Rietschel, E.T., and Ulmer, A.J. (1991). Inhibition of endotoxin-induced interleukin-6 production by synthetic lipid A partial structures in human peripheral blood mononuclear cells. *Infect. Immun.* 59, 4655–4664.
- Weaver, G.C., Villar, R.F., Kanekiyo, M., Nabel, G.J., Mascola, J.R., and Lingwood, D. (2016). In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates. *Nat. Protoc.* 11, 193–213.
- Weisend, C.M., Kundert, J.A., Suvorova, E.S., Prigge, J.R., and Schmidt, E.E. (2009). Cre activity in fetal albCre mouse hepatocytes: Utility for developmental studies. *Genesis* 47, 789–792.
- Wolf, J., Rose-John, S., and Garbers, C. (2014). Interleukin-6 and its receptors: a highly regulated and dynamic system. *Cytokine* 70, 11–20.
- Wu, X., Yang, Z.Y., Li, Y., Hogerkorp, C.M., Schief, W.R., Seaman, M.S., Zhou, T., Schmidt, S.D., Wu, L., Xu, L., et al. (2010). Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. *Science* 329, 856–861.
- Xu, E., Pereira, M.M.A., Karakasilioti, I., Theurich, S., Al-Maarri, M., Rappl, G., Waisman, A., Wunderlich, F.T., and Brüning, J.C. (2017). Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance. *Nat. Commun.* 8, 14803.
- Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020). Effective treatment of severe COVID-19 patients with tocilizumab. *Proc. Natl. Acad. Sci. USA* 117, 10970–10975.
- Yassine, H.M., Boyington, J.C., McTamney, P.M., Wei, C.J., Kanekiyo, M., Kong, W.P., Gallagher, J.R., Wang, L., Zhang, Y., Joyce, M.G., et al. (2015). Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. *Nat. Med.* 21, 1065–1070.
- Zhang, J., Supakorndej, T., Krambs, J.R., Rao, M., Abou-Ezzi, G., Ye, R.Y., Li, S., Trinkaus, K., and Link, D.C. (2019). Bone marrow dendritic cells regulate hematopoietic stem/progenitor cell trafficking. *J. Clin. Invest.* 129, 2920–2931.
- Zhao, Y., Zagani, R., Park, S.M., Yoshida, N., Shah, P., and Reinecker, H.C. (2019). Microbial recognition by GEF-H1 controls IKK $\epsilon$  mediated activation of IRF5. *Nat. Commun.* 10, 1349.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Rat anti-murine CD19-PerCP-Cy5.5	BioLegend	Cat#115533; RRID: AB_2259869
Rat anti-murine -B220-FITC	BD PharMingen	Cat#553087; RRID: AB_394617
Rat anti-murine -MHCII-BV510	BioLegend	Cat#107636; RRID: AB_2734168
Rat anti-murine -CD3-BV785	BioLegend	Cat#100232; RRID: AB_2562554
Hamster anti-murine -CD11c-PE/Cy7	BioLegend	Cat#117318; RRID:AB_493568
Rat anti-murine-CD169-FITC	BioRad	Cat#MCA884FT; RRID:AB_1100895
Rat anti-murine CD138-BV421	BD Horizon	Cat#562610
Rat anti-murine B220-BV605	BD Horizon	Cat#563708
Rat anti-murine IL6R-APC	BioLegend	Cat#115812; RRID: AB_2296238
Rat anti-murine CD11b-APC	BioLegend	Cat#101212; RRID: AB_312795
Rat anti-murine gp130-APC	eBiosciences	Cat#17-1302-82; RRID: AB_10670874
Rat anti-murine CD11b-FITC	BioLegend	Cat#101206; RRID: AB_312789
Rat anti-murine Siglec H-APC	BioLegend	Cat#129612; RRID: AB_10641134
Rat anti-murine CD93-PE	BioLegend	Cat#136503; RRID: AB_1967094
Rat anti-murine CD8 $\alpha$ -BV605	BioLegend	Cat#100744; RRID: AB_2562609
Rat anti-murine DCIR2-PE	BioLegend	Cat#124905; RRID: AB_1186128
Rat anti-murine Ly6C-BV650	BioLegend	Cat#128035; RRID: AB_2562352
Rat anti-murine F4/80-Alexa 488	Thermo Fisher	Cat#53-4801-82; RRID: AB_469915
Rat anti-murine pY705 STAT3-PE	BioLegend	Cat#651004; RRID: AB_2571892
Goat anti-murine IgM-HRP	Southern Biotech	Cat#1021-05; RRID:AB_2794240
Sheep anti-murine IgG-HRP	GE Healthcare	Cat# NA931-1ML
<b>Bacterial and virus strains</b>		
New Caledonia/20/1999 (NC99) influenza virus	International Reagent Resource	Cat# FR-395
A/Puerto Rico/8/34 (PR8) influenza virus	<a href="#">Balazs et al., 2013</a>	N/A
<b>Chemicals, peptides, and recombinant proteins</b>		
LIVE/DEAD Fixable Blue Dead Cell Stain	Thermo Fisher	Cat#L34961
Sigma Adjuvant System	Sigma-Aldrich	Cat#S6322
Collagenase D (Roche collagenase D)	Roche	Cat#11088858001
ACK lysis buffer	Lonza	Cat#10-548E
Tissue-Tek O.C.T Compound	Sakura	Cat#4583
Background Sniper Blocking Reagent	Biocare Medical	Cat#902-966-082317
HA Trimer (NC99)	Produced in house ( <a href="#">Weaver et al., 2016</a> )	N/A
gp120 monomer	Produced in house ( <a href="#">Wu et al., 2010</a> )	N/A
ovalbumin	Biosearch Technologies	Cat#O-1000-100
293fectin Reagent	Invitrogen	Cat#12347019
Ni-Sepharose excel Affinity Medium	GE Healthcare	Cat#GE17-3712-02
LPS ( <i>Escherichia coli</i> O111:B4)	Sigma	Cat#L2630
Tetramethylbenzidine (TMB)	Sigma	Cat#T0440
Murine GM-CSF	eBiosciences	Cat#14-8331-80
Murine IL-4	MBL	Cat#JM-4138-10
Murine recombinant IL-6	R&D systems	Cat#406-ML-005
Murine recombinant IL-6-IL6R $\alpha$	R&D systems	Cat#9038-SR-025
Murine recombinant IL6R	R&D systems	Cat#1830-SR-025

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Diphtheria toxin (DT)	Sigma	Cat#D0564
Streptavidin conjugated APC	ThermoFisher	Cat# S32362
<b>Critical commercial assays</b>		
Mouse IL-6 ELISA Kit	R&D systems	Cat#M6000B
Mouse IL6R $\alpha$ ELISA Kit	Abcam	Cat#ab203360
BirA Biotin-Protein Ligase Bulk Reaction Kit	Avidity	Cat#Bulk BirA
<b>Experimental models: organisms/strains</b>		
Mouse: C57BL/6J	Jackson laboratory	Stock no. 000664
Mouse: <i>Tcra</i> <sup>-/-</sup>	Jackson laboratory	Stock no. 002116
Mouse: <i>Zbtb46</i> -DTR	Jackson laboratory	Stock no. 019506
Mouse: MHCII deficient ( <i>H2<sup>dlAb1-Ea</sup></i> )	Jackson laboratory	Stock no. 003584
Mouse: <i>Irf5</i> <sup>-/-</sup>	<a href="#">Zhao et al., 2019</a>	N/A
Mouse: <i>Il6</i> <sup>-/-</sup>	Jackson laboratory	Stock no.002650
Mouse: <i>Il12p40</i> <sup>-/-</sup>	Jackson laboratory	Stock no.002693
Mouse: <i>Zbtb46</i> cre	Jackson laboratory	Stock no.028538
Mouse: <i>IL6ra</i> <sup>fllox/fllox</sup>	Jackson laboratory	Stock no.012944
Mouse: <i>Adam17</i> <sup>fllox/fllox</sup>	Jackson laboratory	Stock no.009597
Mouse: <i>Irf5</i> <sup>fllox/fllox</sup>	Jackson laboratory	Stock no.017311
Mouse: <i>Batf3</i> <sup>-/-</sup>	Jackson laboratory	Stock no.013755
Mouse: <i>Tlr4</i> <sup>-/-</sup>	Jackson laboratory	Stock no.029015
Mouse: <i>Tlr7</i> <sup>-/-</sup>	Jackson laboratory	Stock no.008380
Mouse: <i>Ifnar1</i> <sup>-/-</sup>	Jackson laboratory	Stock no.32045-JAX
Mouse: cDC- <i>Il6r</i> <sup>-/-</sup>	This paper	
Mouse: cDC- <i>Irf5</i> <sup>-/-</sup>	This paper	
Mouse: cDC- <i>Adam17</i> <sup>-/-</sup>	This paper	
<b>Software and algorithms</b>		
FlowJo v.9.3.2	TreeStar	<a href="https://www.flowjo.com">https://www.flowjo.com</a> ; RRID: SCR_008520
Prism 7	GraphPad	<a href="https://www.graphpad.com">https://www.graphpad.com</a> ; RRID: SCR_002798
<b>Other</b>		
96 well microtiter plates	Fisher Scientific	Cat#439454
48 well non-treated plates	CytoOne	Cat#CC7672-7548
10 cm non-treated plates	CytoOne	Cat#CC7672-3614
Superdex 200 10/300 Column	GE Healthcare	Cat#17517501

**RESOURCE AVAILABILITY**

Further information and requests for reagents should be directed to and will be fulfilled by Daniel Lingwood.

**Lead contact**

Daniel Lingwood ([dlingwood@mgh.harvard.edu](mailto:dlingwood@mgh.harvard.edu)).

**Materials availability**

There are no restrictions to the availability of materials in this study

**Data and code availability**

N/A

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

For all experiments, animals were maintained within Ragon Institute's HPPF barrier facility and were conducted with institutional IACUC approval (MGH protocols 2014N000252 and #2014N000005).

### Transgenic mice

The following mice were purchased from Jackson Laboratories: C57BL/6, *Tcra*<sup>-/-</sup>, *Zbtb46-DTR*<sup>+/+</sup>, MHCII deficient (homozygous *H2<sup>dIAb1-Ea</sup>*), *Il6*<sup>-/-</sup>, *Il12p40*<sup>-/-</sup>, *Zbtb46-cre*<sup>+/+</sup>, *Il6ra*<sup>flox/flox</sup>, *Irf5*<sup>flox/flox</sup>, *Adam17*<sup>flox/flox</sup>, *Batf3*<sup>-/-</sup>, *Tlr4*<sup>-/-</sup>, *Tlr7*<sup>-/-</sup> and *Ifnar1*<sup>-/-</sup>. The cDC-*Il6ra*<sup>-/-</sup>, cDC-*Irf5*<sup>-/-</sup> and cDC-*Adam17*<sup>-/-</sup> genotypes were generated by crossing the *Zbtb46-cre*<sup>+/+</sup> with *Il6ra*<sup>flox/flox</sup>, *Irf5*<sup>flox/flox</sup>, or *Adam17*<sup>flox/flox</sup>, respectively. The *Irf5*<sup>-/-</sup> animals were as described (Zhao et al., 2019). All genotypes were confirmed by PCR, according to the instructions provided by Jackson Laboratories. Animal experiments were performed on mice aged 6–12 weeks.

### Bone marrow chimeras

Bone marrow chimeras were generated as described (Meredith et al., 2012). C57BL/6 mice were lethally irradiated at 950 cGrey and intravenously received  $1 \times 10^7$  BM cells per mouse from one of two donors: either *Zbtb46-DTR*<sup>+/+</sup> (generating chimeras with 100% zDCs) or a mixture of *Zbtb46-DTR* (50%) + MHCII deficient (homozygous *H2<sup>dIAb1-Ea</sup>*) (50%). The bone marrow was reconstituted for 8 weeks and our immune challenges were then conducted over the next two-week period during which time diphtheria toxin (DT) (Sigma D0564) was administered IP, first with an initial shot 20ng/g body weight and then 4ng/g every other day.

### Splenectomized mice

Mouse splenectomies were as described (Rubtsov et al., 2005). Prior to the surgery animals were treated buprenorphine HCl (0.1 mg/kg sc) 30 minutes prior to the surgical procedure as pre-emptive analgesia. The left flank skin was then shaved and then swabbed with a sterile sponge moistened with 5% betadine and then 70% ethanol. Following this, the animals were anesthetized with ketamine (0.10 mg/g i.p.) and xylazine (0.012 mg/g i.p.). After confirming the depth of anesthesia using toe pinch, a 1.5-2cm incision was made within left hypochondrium using surgical scissors. Animals were closely observed for normal rhythmic breathing pattern throughout this time. The spleen was then exposed and gently pushed free of adjacent tissue using blunt-ended scissors and forceps. The splenic artery was then tied off at the superior pole by a single knot tie of 3-0 plane CATGUT. An additional knot was then made at the efferent venule, exiting the spleen at the inferior pole. The connective tissue was cut away and the spleen was removed by gently cutting on the splenic side of each knotted blood vessel. The surgical wound was then closed with sterile suturing of the peritoneum. The skin layer was then closed with four to five autoclips, using an autoclip wound-clip applicator. The animals were then with gentamicin IM (40mg/kg). For sham controls the same surgery was performed, except the spleen was not removed and the blood vessels were not ligated. After surgery, the mice were observed daily for two weeks to ensure recovery before beginning immunization experiments. Autoclips were removed 7 to 10 days post-surgery, using autoclip-removing forceps.

## METHOD DETAILS

### Protein antigens

Trimeric influenza hemagglutinin (HA) or and monomeric gp120 (resurfaced core 3) were purified as described (Weaver et al., 2016; Wu et al., 2010). 293F cells grown in Freestyle media (Life Technologies) were transfected with 500 µg/L of HA or probe plasmid (293fectin™ Reagent, Life Technologies). At day 5, the culture was centrifuged (2,000 × g, 10 min) and the supernatant was filtered (VacuCap 8/0.2 µm filters, Pall Corporation) and loaded on Ni Sepharose FF resin (GE Healthcare) by gravity flow. The resin was washed (6 column volumes of PBS containing 20mM imidazole) and then HA or gp120 was eluted in 500mM imidazole. The proteins were then concentrated (Amicon Ultra concentrators, 30kDa, cut off), and were separated by size exclusion FPLC using a Superdex 200 10/300 column (GE Healthcare). Trimeric HA or monomeric gp120 was then collected, concentrated and stored at -80°C. To construct a fluorescent version of HA, trimers bearing Avi tag (a site specific biotinylation sequence) were biotinylated using the commercial BirA biotin ligase (Avidity) and then labeled fluorescently with streptavidin conjugated APC (Life Technologies) as described previously (Weaver et al., 2016). Ovalbumin was purchased commercially (Biosearch Technologies).

### Immunization regimens

Mice were intravenously immunized with 15µg of either HA, gp120 or ovalbumin, each supplemented with Sigma adjuvant system (Sigma). Sigma adjuvant (formally known as Ribi (Yassine et al., 2015)) is an oil-in-water emulsion which was initially adjusted with ddH<sub>2</sub>O so that its immunostimulant, the TLR4 agonist monophosphoryl Lipid A and potent inducer of IL-6 release (Matsuura et al., 1999; Wang et al., 1991), is present in the inoculum at 12.5µg [~100x less than the LD50 for lipid A-induction of septic shock in B6 mice (Galanos et al., 1979)]. To capture the primary antibody response from the spleen, blood was sampled at days 3, 7 and 14 post-immunization [the primary IgM + IgG response against these proteins peaked at day 14, consistent with previous studies of blood-based responses against protein antigens in mice (Rubtsov et al., 2005; Sangesland et al., 2020; Song and Cerny, 2003)]. In some experiments, the HA immunization regimen also included intraperitoneal injection with recombinant murine IL-6 (rIL6) (R&D systems) or recombinant murine sIL6R (R&D systems). These IP injections occurred daily (100ng/mouse), starting one day before the IV immunization of HA antigen, and up to day 14. To analyze plasmablast differentiation into plasma cells during these responses, animals were also harvested for splenocytes at days 3 and 7 days post-immunization.

### ELISA

To evaluate antibody responses in the serum, MaxSorp plates (Nunc) were coated overnight with 0.2 µg/well of either HA, gp120, or ovalbumin. The plates were blocked by 3% skimmed milk for (1h) at room temperature. After blocking, the plates were incubated for

1h with serial dilutions of pre- and post-immune sera. The samples were initially diluted at 1:20 in PBS followed by a 1:5 serial dilution in the same buffer. The wells were then washed 3x with PBST, incubated for 1h with a 1:5000 dilution of either: goat anti-murine IgM (IgG-HRP, Southern Biotech) or sheep anti-murine IgG (HRP-IgG, GE Healthcare). The plates were washed (3x PBST) and then developed using TMB substrate (Dako). The developer reaction was quenched by the addition of 1N sulphuric acid and the plates were then read at 450nm using a Spectomax Plus (Molecular Devices). Antibody endpoint dilutions were interpolated using Graphpad Prism version 5.0 (GraphPad Software Inc.), as previously described (Kanekiyo et al., 2013; Yassine et al., 2015). The concentrations of IL-6 and sIL6R in mouse sera were quantified according to the instructions provided in commercial sandwich ELISA kits from R&D Systems (Quantikine-M6000B) and Abcam (ab203360), respectively.

### Imaging antigen uptake by immunofluorescence

To visualize antigen uptake from the spleen marginal zone into the follicles, zDCs chimeras (DT treated and untreated) mice were injected intravenously by 30  $\mu$ g of HA-APC. The spleens were then removed at 1 and 4 h post-injection and then cut into ~5mm thick pieces. These pieces were submerged in O.C.T Compound (Tissue-Tek; Sakura) and then frozen by immersing the sample in isobutene that was housed in a metal container externally exposed to liquid nitrogen. The resultant frozen tissue block was stored at  $-80^{\circ}$  C. For immunostaining, the tissue sections were first sectioned on a cryostat (40  $\mu$ m thick) and air-dried overnight. The sections were then fixed in ice-cold acetone for 10 min, outlined with a wax pen, and rehydrated in PBS for 5 min. The sections were then blocked with Background sniper (Biocare) for 15 min (room temperature within a dark humid chamber) and then incubated for 1 h in the same chamber with anti-CD169-FITC (BioRad) to stain metalophilic macrophages and delineate the spleen follicles (the antibody was diluted 1:500 in PBS containing 0.1% Tween20). The sections were then washed with PBS in a coplin jar (3x, five min each) and then slide-mounted using ProLong Gold Antifade (Invitrogen). Images of the fluorescent APC and FITC were then acquired using a confocal fluorescent microscope (Zeiss LSM 510). To quantify antigen uptake from the spleen marginal zone, the mean fluorescence intensity of HA-APC present within the CD169-delineated spleen follicles was quantified using Zeiss "Zen" 2009 LSM imaging acquisition software in 10 replicates within each of n = 3 DT-treated or n = 3 DT-untreated zDCs chimeras.

### Isolation of splenocytes and flow cytometry

Mouse spleens were first disrupted in R10 (RPMI with 10% FBS) containing 1mg/ml collagenase D (Roche collagenase D). After 30 min, the suspension was passed through a 70  $\mu$ m cell strainer and then lysed with the ACK lysis buffer system to remove erythrocytes (Lonza). The splenocytes were then washed in PBS and then stained with viability dye (Aqua or Blue Viability at 0.025 mg/ml; ThermoFisher) before our staining panels were applied. Staining panels were derived from the following fluorescently conjugated anti-murine antibodies, each used at a final dilution of 1:100 in PBS: CD11c-PE Cy7 (N418, Biolegend); B220-BV605 (RA3-6B2, BD Horizon); B220-FITC (RA3-6B2, BD PharMingen); MHCII-BV510 (M5/114.15.2, Biolegend); CD3-BV785 (17A2, Biolegend); CD19-PerCP/Cy5.5 (6D5, Biolegend); IL6R-APC (D7715A7, Biolegend); CD11b-APC (M1/70, Biolegend); B220-FITC (RA3-6B2, BD PharMingen); CD138-BV421 (281-2, BD Horizon); gp130-APC (KGP130, eBioscience); CD11b-FITC (M1/70, Biolegend); Siglec-H-APC (551, Biolegend); CD93 (AA4.1, Biolegend); CD8 $\alpha$ -BV605 (53-6.7, Biolegend); DCIR2-PE (33D1, Biolegend); Ly6C-BV650 (HK1.4, Biolegend); F4/80-Alexa 488 (BM8, ThermoFisher). Samples were assayed on a 5 laser LSR Fortessa (BD Biosciences) and data was analyzed using FlowJo software version 9.3.2 (TreeStar).

### FACS and immunoblotting

IRF5 is a cytosolic protein, so we isolated cDCs by fluorescence-activated cell sorting (FACS) to confirm reduction in this cell lineage within the *cDC-Irf5<sup>-/-</sup>* genotype. Splenocytes from WT and *cDC-Irf5<sup>-/-</sup>* mice were processed as above and then stained with Blue viability dye (0.025mg/ml; ThermoFisher) and then the following antibody flow panel (wherein each antibody was used at a final dilution of 1:100): CD3-BV785 (17A2, Biolegend); B220-FITC (RA3-6B2, BD PharMingen); CD11c-PE Cy7 (N418, Biolegend); and MHCII-BV510 (M5/114.15.2, Biolegend). We sorted 200,000 sorted cDCs (B220<sup>+</sup>/CD3<sup>+</sup>/CD11c<sup>hi</sup>/MHCII<sup>+</sup>) from each animal genotype. For immunoblotting, the cDCs cells were lysed in 100 $\mu$ l of 1X RIPA buffer (ThermoFisher) and the lysate was then immersed in 1x Laemmli buffer (Sigma). After boiling the sample (5 min at 100 $^{\circ}$ C) the samples were separated by SDS-PAGE. The proteins were then transferred overnight (4 $^{\circ}$ C at 30V) onto nitrocellulose membrane. The membranes were blocked with 5% BSA and then probed for 1.5h at room temperature with a rabbit anti-murine IRF5 antibody (ab21689, Abcam) at a dilution of 1/1000 in TBS containing 1% BSA. The membranes were then washed (3x TBST) and incubated for 1h with secondary antibody (anti Rabbit-HRP) at a dilution of 1/2500 in TBS containing 1% BSA. Following four times washing with TBST the membrane was developed with ECL Plus reagent (Pierce). As a loading control, the samples were also blotted with mouse anti- $\beta$ -Actin (8H10D10, Cell Signaling Technology) (1/10000 in 1% BSA) and anti-mouse HRP (1/2500).

### B cell stimulation *in vitro*

Splenocytes from both immunized and unimmunized animals were harvested as described above. From each animal, four replicates of five million splenocyte cultures were grown for 20 minutes at 37 $^{\circ}$ C in 5 mL of serum-free (SF) culture medium (RPMI-1640, phenol red free, 1% glutamine and 5% penicillin-streptomycin) or SF containing freshly 400ng/ml IL6-sIL6R $\alpha$  (= Hyper-IL6; Fischer et al., 1997) (9038-SR-025, R&D Systems). After this culture period, the cells were pelleted, fixed and then permeabilized to enable intracellular staining using pY705 STAT3-PE (BioLegend) along with extracellular markers [B220-FITC, MHCII-BV510, CD138-BV421, CD3-BV786 and gp130-APC], according to the True-Phos<sup>TM</sup> Protocol provided by Biolegend (Xu et al., 2017). The samples were



assayed on a 5 laser LSR Fortessa (BD Biosciences) and data was analyzed using FlowJo software version 9.3.2 (TreeStar) as described above.

### Simulation of bone marrow-derived dendritic cells *in vitro*

Bone marrow-derived dendritic cells (BMDCs) cells were generated as performed previously (Park et al., 2019). In this method, bone marrow cells from femurs and tibia were first flushed with PBS and the red blood cells were then depleted using ACK lysis buffer. The remaining marrow cells were plated in 10 cm non-treated plate (CytoOne) in RPMI-1640 media supplemented with 10% FBS, 1% penicillin/streptomycin, murine GM-CSF (10ng/ml; eBioscience) and murine IL-4 (10ng/ml; MBL). These cells were cultured at 37°C, 5%CO<sub>2</sub> for six days, where fresh media was added every 2 days. On day six, the floating and loosely attached cells [representing the BMDCs (Park et al., 2019)] were collected. BMDC were then divided into three groups for immune stimulation (10<sup>6</sup> cells/well within 48-well flat-bottomed plates containing RPMI-1640 media): 1) PBS control; 2) stimulation with 1 µg/ml of recombinant murine IL-6 (rIL6) (R&D systems); or stimulation with 1 µg/ml of bacterial LPS (Sigma). The stimulation was for 6h in supernatants were then analyzed by ELISA to measure sIL6R as described earlier.

### AAV sIL6R production

AAV virus encoding amino acid residues 1-357 of murine sIL6R was cloned into an AAV transfer vector. This vector was previously described (Balazs et al., 2011) but modified to contain the CAG promoter and rabbit beta globin polyadenylation signal. Briefly, recombinant AAV was produced via transient transfection of 293T cells with a mixture of plasmid DNAs consisting of the transfer vector, pAAV2/8-SEED and pHELP (Applied Viromics) and purified via PEG precipitation of collected supernatants, CsCl<sub>2</sub> ultracentrifugation and fractionation followed by buffer exchange using a 100kDa MWCO centrifugal filter (Millipore) (Balazs et al., 2011). The virus was titered as using primers specific for the CMV enhancer region to obtain a final titer via SYBR Green-based qPCR against a diluted plasmid standard. Aliquots of titered vector were stored at -80°C and were thawed slowly on ice and diluted in PBS to achieve the predetermined dose (1.00E+10 genome copies / 20 g mouse) in a 200µl volume.

### Bacterial and viral immune challenges

To explore the pharmacokinetics of IL-6 post-immune stimulation in our transgenic animals, Sigma Adjuvant containing 12.5µg of bacterial lipid A was injected IV, as described earlier, and blood was sampled both before and then 3, 7, and 14 days post challenge. In some experiments, this was preceded by AAV-gene delivery of murine sIL6R in cDC-*Il6ra*<sup>-/-</sup> mice, using the AAV construct described above and which was administered IV at 1.00E+10 genome copies / 20 g mouse. Three weeks after delivering the AAV construct, the lipid A IV challenge regimen was then performed. Serum concentration of sIL6R and IL-6 were measured by ELISA at each sampling period.

To explore the pharmacokinetics of IL-6 following viral challenge in our transgenic animals, we deployed two murine models of influenza virus infection. In the first model of infection, mice anesthetized by isoflurane inhalation and then intranasally infected using a sublethal dose of New Caledonia/20/1999 (NC99) influenza virus (10<sup>5.0</sup> TCID<sub>50</sub> units/ml). NC99 infects and propagates within mice but does not cause disease (Amitai et al., 2020; Glaser et al., 2007; Sangesland et al., 2019). Blood was sampled both before and then 3, 7, and 14 days post-viral challenge. In some experiments, this was preceded by AAV-gene delivery of murine sIL6R in cDC-*Il6ra*<sup>-/-</sup> mice, as described above and serum sIL6R and IL-6 concentrations were measured by ELISA at each sampling period. In the second model of infection, cDC-*Il6ra*<sup>-/-</sup> mice in which sIL6R concentration was and was not restored by AAV mediated gene delivery, were anesthetized by isoflurane inhalation and then intranasally infected with a 5xLD50 dose of A/Puerto Rico/8/34 (PR8) influenza virus. Subsequent morbidity (weight loss) was measured daily and the animals were humanly euthanized when they reached < 80% body weight.

### QUANTIFICATION AND STATISTICAL ANALYSIS

Multiple comparisons were evaluated by ANOVA with Tukey's test and single comparisons were assessed by two-sided Student's t tests. Morbidity rates were evaluated using F-tests to compare slopes. An alpha value of 0.05 was deployed throughout. All statistical analyses were performed using Graphpad Prism version 5.0 (GraphPad Software Inc.).